MedTrace Logo

Changes in Eosinophil Cationic Protein and Sputum Eosinophils Following Allergen Immunotherapy

NCT07694947 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-18

No results posted yet for this study

Summary

Asthma is a chronic heterogeneous inflammatory airway disease affecting millions worldwide and remains a major global health burden. Despite advances in pharmacological therapy, a substantial proportion of patients continue to experience uncontrolled symptoms due to persistent airway inflammation and disease heterogeneity.

Conditions

  • Allergic Asthma

Interventions

DRUG

Allergen Immunotherapy Extract

Patients diagnosed with allergic asthma that was partially controlled under standard medical therapy indicated for allergen immunotherapy

Sponsors & Collaborators

  • Mansoura University Hospital

    lead OTHER

Principal Investigators

  • Mohamed AbdElmoniem · Lecturer of chest medicine faculty of medicine Mansoura university

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-07-01
Completion
2024-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07694947 on ClinicalTrials.gov